CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that it has signed a ten-year agreement with Fresenius Kabi for the production of INTERCEPT Blood System sets. This ...

The INTERCEPT Blood System for Red Blood Cells is designed to inactivate blood-borne pathogens and donor leukocytes in RBCs intended for transfusion. The RBC system is designed to prevent pathogen ...

Growing Demand for Cerus’ INTERCEPT® Pathogen Inactivation System for Plasma Drives Additional Investment in Microsize’s Particle Sizing Services. QUAKERTOWN, Pa.--(BUSINESS WIRE)--Microsize today ...

Presentations and abstracts showcase the broad applicability and expected benefits of the INTERCEPT Blood System for platelets, plasma, IFC, and red blood cells CONCORD, Calif.--(BUSINESS WIRE)-- ...

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the CE mark approval of its next-generation LED-based illumination device, or the INT200, for the INTERCEPT Blood ...

“ With the INTERCEPT Blood System for platelets being adopted so rapidly in the U.S. market, I am proud to say that on a run-rate basis, more than half of platelets in the U.S. are now treated with ...

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced it has received approval from Health Canada to extend the storage of platelets treated with the INTERCEPT Blood System ...

Regulatory Approval Allows Company to Initiate Commercialization of the Illumination Device throughout the European Union CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (CERS) announced today ...